Trial Profile

Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Monalizumab (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms MIMOSA

Most Recent Events

22 Oct 2024 Status changed from discontinued to completed.
10 Dec 2022 Status changed to discontinued , according to Results presented at the 45th Annual San Antonio Breast Cancer Symposium
10 Dec 2022 Primary endpoint has not been met (Response; number of patients with partial response or complete response) , according to Results safety data presented at the 45th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com